ETF Movers on Wednesday: TAN and NUGO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: NASDAQ.COM
ETF Performance: The Nuveen Growth Opportunities ETF is underperforming, down approximately 2.1% in Wednesday afternoon trading.
Weakest Components: Key contributors to the ETF's decline include Arista Networks, which fell by about 6.9%, and Dexcom, which decreased by about 3.3%.
Market Context: The article highlights the performance of specific ETFs and their components, indicating broader market trends.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 71.900
Low
68.00
Averages
82.54
High
100.00
Current: 71.900
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Capitalization Comparison: DexCom vs First Solar
- Market Cap Comparison: DexCom Inc has a market capitalization of $27.57 billion, compared to First Solar Inc's $25.56 billion, indicating DexCom's relative strength in the market, which may attract more attention from large investors.
- Investor Misconceptions: Many novice investors often mistakenly compare companies solely based on stock price, but market capitalization provides a more accurate assessment of company value, aiding investors in making more informed decisions.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs are willing to hold the stock, particularly as large funds tend to focus on companies valued over $10 billion.
- Stock Performance: As of Thursday's close, DexCom's stock rose approximately 0.6%, while First Solar's stock remained flat, reflecting positive market sentiment towards DexCom, which could further drive its market cap growth.
See More
Dexcom Launches New Continuous Glucose Monitoring System
- Product Innovation: Dexcom's newly launched Dexcom Flex system is specifically designed for adults with Type 2 diabetes who are not on intensive insulin therapy, providing real-time glucose data and personalized behavioral insights aimed at enhancing patient self-management and improving health outcomes.
- Market Expansion: The system will soon be available in Germany, marking a significant step for Dexcom in broadening access to CGM technology, particularly for patient groups that have historically had limited access to such technologies.
- Health Impact: Studies indicate that CGM use among Type 2 diabetes patients can lead to reductions in diabetes-related hospitalizations and lower cardiovascular risks, and the introduction of Dexcom Flex is expected to further promote this positive trend.
- Personalized Care: Dexcom Flex emphasizes personalized diabetes guidance, helping patients build confidence in understanding their glucose levels early in their journey, thereby fostering behavioral changes that can lead to improved quality of life and health outcomes over the long term.
See More
DexCom Stock Rebounds with Optimistic Growth Outlook
- Stock Rebound: DexCom's stock surged 6.59% on Friday, closing at $61.63 per share, effectively reversing a two-day decline as investor sentiment improved due to its enhanced growth outlook for the year.
- Revenue Growth Target: During its investor day, DexCom set an organic revenue growth target of 10% annually through 2030, which is expected to drive long-term growth and bolster market confidence in the company.
- Margin Outlook Upgrade: The company raised its non-GAAP gross margin outlook to a range of 67% to 69%, up from the previous 63% to 64%, while also increasing its non-GAAP operating profit margin to 29% to 30%, indicating a significant improvement in profitability.
- Board Expansion Plan: DexCom announced plans to add two independent directors with expertise in medical technology and operations, following collaboration with activist investor Elliott Investment Management LP, which will increase the total number of independent directors to six, thereby enhancing corporate governance.
See More
Healthcare Stocks Decline on Friday Afternoon
- Healthcare Index Decline: The NYSE Healthcare Index fell by 0.9% on Friday afternoon, reflecting growing concerns in the market regarding the healthcare sector, which could impact investor confidence and lead to capital outflows from this segment.
- Market Reaction: The overall decline in healthcare stocks may be linked to economic data or policy changes, prompting investors to monitor future market dynamics to assess the long-term implications for the healthcare industry.
- Investor Sentiment: As healthcare stocks decline, investors may reassess their portfolios, particularly in the context of increasing economic uncertainty, potentially leading to a shift of funds towards other sectors.
- Industry Outlook: Short-term volatility in the healthcare sector could affect companies' financing capabilities and R&D investments, thereby impacting future innovation and market competitiveness.
See More
Microsoft Shares Rise as ServiceNow Partners with Experian
- Microsoft Shares Rise: Microsoft's stock rose nearly 4% following Bill Ackman's disclosure of accumulating shares, as he finds the company's valuation to be 'highly compelling' after its second-quarter earnings report.
- ServiceNow Partnership: ServiceNow's stock increased nearly 5% after announcing a multiyear partnership with Experian to develop autonomous AI agents, which is expected to enhance their competitive edge in the AI market.
- Ford Stock Decline: Ford's shares fell about 7% after a previous surge of over 20%, with analysts noting that recent gains were driven more by enthusiasm around battery storage ambitions than by solid fundamentals.
- Figma Earnings Beat: Figma's stock surged nearly 9% after reporting first-quarter earnings of 10 cents per share on revenues of $333 million, exceeding analyst expectations of 6 cents per share, indicating strong market demand.
See More
U.S. Stocks Retreat as Tech Shares Decline
- Market Retreat: The three major indexes fell on Friday due to weakness in technology stocks and rising Treasury yields, with the benchmark 10-year yield climbing to 4.58%, putting pressure on growth stocks as investors rotated between high-flying tech and lagging value stocks.
- Disappointment from U.S.-China Summit: The meeting between Trump and Xi failed to deliver major breakthroughs, particularly disappointing investors with Boeing's aircraft commitment, which fell short of the anticipated 500 planes, coming in at around 200, thus pressuring Boeing's stock.
- Volatility in Arm Holdings: Shares of Arm Holdings dropped 7% on Friday, continuing a volatile trend following its earnings report, with Jim Cramer cautioning that the market is anxious about its ability to secure sufficient manufacturing capacity at TSMC for its AGI CPU, recommending a reduction in exposure.
- Rapid Fire Stock Review: Stocks mentioned at the end of Friday's video included Applied Materials, Dexcom, and Texas Roadhouse, with Jim Cramer's charitable trust holding positions in Arm, Boeing, and Nvidia, emphasizing the importance of timely trade alerts for subscribers.
See More
Market Capitalization Comparison: DexCom vs First Solar
- Market Cap Comparison: DexCom Inc has a market capitalization of $27.57 billion, compared to First Solar Inc's $25.56 billion, indicating DexCom's relative strength in the market, which may attract more attention from large investors.
- Investor Misconceptions: Many novice investors often mistakenly compare companies solely based on stock price, but market capitalization provides a more accurate assessment of company value, aiding investors in making more informed decisions.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs are willing to hold the stock, particularly as large funds tend to focus on companies valued over $10 billion.
- Stock Performance: As of Thursday's close, DexCom's stock rose approximately 0.6%, while First Solar's stock remained flat, reflecting positive market sentiment towards DexCom, which could further drive its market cap growth.
See More
Dexcom Launches New Continuous Glucose Monitoring System
- Product Innovation: Dexcom's newly launched Dexcom Flex system is specifically designed for adults with Type 2 diabetes who are not on intensive insulin therapy, providing real-time glucose data and personalized behavioral insights aimed at enhancing patient self-management and improving health outcomes.
- Market Expansion: The system will soon be available in Germany, marking a significant step for Dexcom in broadening access to CGM technology, particularly for patient groups that have historically had limited access to such technologies.
- Health Impact: Studies indicate that CGM use among Type 2 diabetes patients can lead to reductions in diabetes-related hospitalizations and lower cardiovascular risks, and the introduction of Dexcom Flex is expected to further promote this positive trend.
- Personalized Care: Dexcom Flex emphasizes personalized diabetes guidance, helping patients build confidence in understanding their glucose levels early in their journey, thereby fostering behavioral changes that can lead to improved quality of life and health outcomes over the long term.
See More
DexCom Stock Rebounds with Optimistic Growth Outlook
- Stock Rebound: DexCom's stock surged 6.59% on Friday, closing at $61.63 per share, effectively reversing a two-day decline as investor sentiment improved due to its enhanced growth outlook for the year.
- Revenue Growth Target: During its investor day, DexCom set an organic revenue growth target of 10% annually through 2030, which is expected to drive long-term growth and bolster market confidence in the company.
- Margin Outlook Upgrade: The company raised its non-GAAP gross margin outlook to a range of 67% to 69%, up from the previous 63% to 64%, while also increasing its non-GAAP operating profit margin to 29% to 30%, indicating a significant improvement in profitability.
- Board Expansion Plan: DexCom announced plans to add two independent directors with expertise in medical technology and operations, following collaboration with activist investor Elliott Investment Management LP, which will increase the total number of independent directors to six, thereby enhancing corporate governance.
See More
Healthcare Stocks Decline on Friday Afternoon
- Healthcare Index Decline: The NYSE Healthcare Index fell by 0.9% on Friday afternoon, reflecting growing concerns in the market regarding the healthcare sector, which could impact investor confidence and lead to capital outflows from this segment.
- Market Reaction: The overall decline in healthcare stocks may be linked to economic data or policy changes, prompting investors to monitor future market dynamics to assess the long-term implications for the healthcare industry.
- Investor Sentiment: As healthcare stocks decline, investors may reassess their portfolios, particularly in the context of increasing economic uncertainty, potentially leading to a shift of funds towards other sectors.
- Industry Outlook: Short-term volatility in the healthcare sector could affect companies' financing capabilities and R&D investments, thereby impacting future innovation and market competitiveness.
See More
Microsoft Shares Rise as ServiceNow Partners with Experian
- Microsoft Shares Rise: Microsoft's stock rose nearly 4% following Bill Ackman's disclosure of accumulating shares, as he finds the company's valuation to be 'highly compelling' after its second-quarter earnings report.
- ServiceNow Partnership: ServiceNow's stock increased nearly 5% after announcing a multiyear partnership with Experian to develop autonomous AI agents, which is expected to enhance their competitive edge in the AI market.
- Ford Stock Decline: Ford's shares fell about 7% after a previous surge of over 20%, with analysts noting that recent gains were driven more by enthusiasm around battery storage ambitions than by solid fundamentals.
- Figma Earnings Beat: Figma's stock surged nearly 9% after reporting first-quarter earnings of 10 cents per share on revenues of $333 million, exceeding analyst expectations of 6 cents per share, indicating strong market demand.
See More
U.S. Stocks Retreat as Tech Shares Decline
- Market Retreat: The three major indexes fell on Friday due to weakness in technology stocks and rising Treasury yields, with the benchmark 10-year yield climbing to 4.58%, putting pressure on growth stocks as investors rotated between high-flying tech and lagging value stocks.
- Disappointment from U.S.-China Summit: The meeting between Trump and Xi failed to deliver major breakthroughs, particularly disappointing investors with Boeing's aircraft commitment, which fell short of the anticipated 500 planes, coming in at around 200, thus pressuring Boeing's stock.
- Volatility in Arm Holdings: Shares of Arm Holdings dropped 7% on Friday, continuing a volatile trend following its earnings report, with Jim Cramer cautioning that the market is anxious about its ability to secure sufficient manufacturing capacity at TSMC for its AGI CPU, recommending a reduction in exposure.
- Rapid Fire Stock Review: Stocks mentioned at the end of Friday's video included Applied Materials, Dexcom, and Texas Roadhouse, with Jim Cramer's charitable trust holding positions in Arm, Boeing, and Nvidia, emphasizing the importance of timely trade alerts for subscribers.
See More
